News - Dainippon Sumitomo Pharma, Perjeta

Filter

Popular Filters

1 to 25 of 46 results

Sunovion’s once-daily epilepsy drug Aptiom debuts in USA

08-04-2014

USA-based Sunovion Pharmaceuticals, a subsidiary of Japanese drug major Dainippon Sumitomo, has launched…

AptiomDainippon Sumitomo PharmaMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalSunovionUSA

EU approval for Dainippon Sumitomo and Takeda’s Latuda

EU approval for Dainippon Sumitomo and Takeda’s Latuda

28-03-2014

Japanese drug majors Dainippon Sumitomo Pharma and Takeda Pharmaceutical have received European Commission…

Dainippon Sumitomo PharmaEuropeLatudaNeurologicalPharmaceuticalRegulationSunovionTakeda Pharmaceuticals

FDA approves Northera for neurogenic orthostatic hypotension

FDA approves Northera for neurogenic orthostatic hypotension

19-02-2014

Shares of US biotech firm Chelsea Therapeutics soared 38% to $6.75 in after-hours trading yesterday,…

BiotechnologyChelsea TherapeuticsDainippon Sumitomo PharmaNorth AmericaNortheraRare diseasesRegulationUSA

Edison Pharma in deal with Dainippon Sumitomo potentially worth $4.3 billion

Edison Pharma in deal with Dainippon Sumitomo potentially worth $4.3 billion

31-01-2014

Privately-held US company Edison Pharmaceuticals has entered into a new strategic alliance valued up…

Dainippon Sumitomo PharmaEdison PharmaceuticalsEPI-589LicensingMetabolicsNeurologicalPharmaceutical

Intercept rockets on positive liver disease drug trial

10-01-2014

Shares of USA-based Intercept Pharmaceuticals tripled to $275.87 by close of trading on January 9, when…

Dainippon Sumitomo PharmaIntercept PharmaceuticalsNephrology and Hepatologyobeticholic acidPharmaceuticalResearch

FDA thumbs up for Sunovion’s Aptiom as once-daily adjunctive for partial-onset seizures

FDA thumbs up for Sunovion’s Aptiom as once-daily adjunctive for partial-onset seizures

09-11-2013

The US Food and Drug Administration on Friday approved Sunovion Pharmaceutical’s (a subsidiary of Japanese…

AptiomDainippon Sumitomo PharmaNeurologicalNorth AmericaPharmaceuticalRegulationSunovion

Report: Latuda has greatest commercial potential among new agents entering the bipolar drug market

Report: Latuda has greatest commercial potential among new agents entering the bipolar drug market

15-10-2013

Dainippon Sumitomo Pharma/Sunovion/Takeda Pharmaceutical’s atypical antipsychotic Latuda (lurasidone)…

Dainippon Sumitomo PharmaGlobalLatudaMarkets & MarketingNeurologicalPharmaceuticalTakeda Pharmaceuticals

Roche investing 800 million Swiss francs to expand biologics production

Roche investing 800 million Swiss francs to expand biologics production

14-10-2013

Roche said this morning it plans to invest 800 million Swiss francs ($879.2 million) within its global…

BiotechnologyEuropeFinancialGenentechKadcylaNorth AmericaPerjetaProductionRoActemraRoche

Sunovion's eslicarbazepine successful in Ph III epilepsy studies

18-09-2013

Sunovion Pharmaceuticals, a US subsidiary of Japan's Dainippon Sumitomo Pharma (TYO: 4506), says that…

Dainippon Sumitomo PharmaeslicarbazepineNeurologicalPharmaceuticalResearchSunovion

Chugai launches Perjeta for breast cancer in Japan

13-09-2013

Japanese drugmaker Chugai Pharmaceutical (TYO: 4519) has launched the anti-cancer agent Perjeta (pertuzumab)…

Asia-PacificChugai PharmaceuticalMarkets & MarketingOncologyPerjetaPharmaceutical

FDA advisory panel backs new indication for Genentech's Perjeta

13-09-2013

The US Food and Drug Administration's Oncologic Drugs Advisory Committee (ODAC) yesterday (September…

BiotechnologyGenentechKadcylaNorth AmericaOncologyPerjetaPharmaceuticalRegulationRoche

Takeda gains first European approval for lurasidone

14-08-2013

Japan's largest drugmaker Takeda Pharma (TYO: 4502) says it has been granted approval by Switzerland's…

Dainippon Sumitomo PharmaEuropeLatudalurasidoneNeurologicalPharmaceuticalRegulationTakeda Pharmaceuticals

Sunovion announces novel drug discovery partnership

14-08-2013

Sunovion Pharmaceuticals, a wholly-owned US subsidiary of Japanese drug major Dainippon Sumitomo Pharma…

AfraxisDainippon Sumitomo PharmaLicensingNeurologicalPharmaceuticalResearchSunovion

Dainippon Sumitomo establishes regenerative and cellular medicine office

12-08-2013

Japanese drug major Dainippon Sumitomo Pharma (TYO: 4506) says that it has set up the Regenerative &…

Asia-PacificBiotechnologyDainippon Sumitomo PharmaPharmaceuticalProductionResearch

UK NICE guidance says breast cancer drug Perjeta not value for money

06-08-2013

The UK's National Health Service (NHS) is to be advised that it should not routinely provide Swiss drug…

BiotechnologyEuropeOncologyPerjetaPharmaceuticalPricingRegulationRoche

Top-line financials for Japanese drug majors

01-08-2013

Among a flurry of first-quarter fiscal 2013/14 financial results released by Japanese drug majors, the…

Dainippon Sumitomo PharmaEisaiFinancialMitsubishi TanabePharmaceuticalTakeda Pharmaceuticals

US District Court issues final judgment in favor of Mylan in Brovana patent dispute

09-07-2013

US generics and specialty drugmaker Mylan (Nasdaq: MYL) revealed yesterday (July 8) that the US District…

BrovanaDainippon Sumitomo PharmaGenericsLegalMylan LaboratoriesNorth AmericaPatentsPerforomistPharmaceuticalRespiratory and PulmonarySunovion

US FDA backs news indications for Latuda; grants Priority Review for Perjeta

02-07-2013

Sunovion Pharmaceuticals, a US subsidiary of Japan's Dainippon Sumitomo Pharma (TYO: 4506), says that…

BiotechnologyDainippon Sumitomo PharmaLatudaNeurologicalNorth AmericaOncologyPerjetaPharmaceuticalRegulationRocheSunovion

Chugai gains Japanese approval for Perjeta and Bonviva

28-06-2013

Japanese drugmaker Chugai Pharmaceutical (TYO: 4519) said this morning (June 28) that it has obtained…

Anti-Arthritics/RheumaticsAsia-PacificBonvivaChugai PharmaceuticalOncologyPerjetaPharmaceuticalRegulationRoche

Top-line financial results from Japanese drug majors

09-05-2013

Among a batch of Japanese drug majors presenting fiscal year 2013 (ended April 2013) financial results,…

Dainippon Sumitomo PharmaFinancialMitsubishi TanabePharmaceuticalShionogiTakeda Pharmaceuticals

Dainippon Sumitomo gains rights to Edison Pharma drug candidates in up to $545 million accord

02-04-2013

Privately-held US firm Edison Pharmaceuticals has entered into a research, development and commercialization…

Dainippon Sumitomo PharmaEdison PharmaceuticalsEPI-589EPI-743LicensingNeurologicalPharmaceuticalResearch

Dainippon Sumitomo partners with Nippon Shinyaku for urology drug AMP-986

12-03-2013

Japanese drugmakers Dainippon Sumitomo Pharma (TYO: 4506) and Nippon Shinyaku (TYO: 4516) have concluded…

AMP-986Asia-PacificDainippon Sumitomo PharmaGenito-urinaryLicensingNippon ShinyakuPharmaceutical

1 to 25 of 46 results

Back to top